These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 6336981

  • 1. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
    Cocconi G, De Lisi V, Boni C, Mori P, Malacarne P, Amadori D, Giovanelli E.
    Cancer; 1983 Feb 15; 51(4):581-8. PubMed ID: 6336981
    [Abstract] [Full Text] [Related]

  • 2. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen.
    Mouridsen HT, Rose C, Engelsman E, Sylvester R, Rotmensz N.
    Eur J Cancer Clin Oncol; 1985 Mar 15; 21(3):291-9. PubMed ID: 3891357
    [Abstract] [Full Text] [Related]

  • 3. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
    Viladiu P, Alonso MC, Avella A, Beltrán M, Borrás J, Ojeda B, Bosch FX.
    Cancer; 1985 Dec 15; 56(12):2745-50. PubMed ID: 3902200
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
    Kaufmann M, Jonat W, Abel U, Hilfrich J, Caffier H, Kreienberg R, Trams G, Brunnert K, Schermann J, Kleine W.
    J Clin Oncol; 1993 Mar 15; 11(3):454-60. PubMed ID: 8445420
    [Abstract] [Full Text] [Related]

  • 5. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.
    Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J.
    J Clin Oncol; 1996 Oct 15; 14(10):2731-7. PubMed ID: 8874334
    [Abstract] [Full Text] [Related]

  • 6. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP, Anton A, Breitbach GP, Colajori E, Tursi JM, Delfino C, Efremidis A, Ezzat A, Fittipaldo A, Kolaric K, Lopez M, Viaro D, HEPI 013 study group.
    J Clin Oncol; 2001 Feb 15; 19(4):943-53. PubMed ID: 11181656
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ.
    Cancer; 1990 Jan 15; 65(2):200-6. PubMed ID: 2403834
    [Abstract] [Full Text] [Related]

  • 8. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoldi L, Camisa R, Bruzzi P.
    Cancer; 2002 Jul 15; 95(2):228-35. PubMed ID: 12124820
    [Abstract] [Full Text] [Related]

  • 9. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG).
    J Natl Cancer Inst; 2002 Jul 17; 94(14):1054-65. PubMed ID: 12122096
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.
    Glick JH, Creech RH, Torri S, Holroyde C, Brodovsky H, Catalano RB, Varano M.
    Breast Cancer Res Treat; 1981 Jul 17; 1(1):59-68. PubMed ID: 6756508
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. A prospective, randomized study.
    Cocconi G, di Blasio B, Bisagni G, Alberti G, Botti E, Anghinoni E.
    Am J Clin Oncol; 1990 Jun 17; 13(3):226-32. PubMed ID: 2189288
    [Abstract] [Full Text] [Related]

  • 13. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL, Gelman RS, Hayes DF, Osteen R, Obando A, Canellos GP, Frei E, Henderson IC.
    J Natl Cancer Inst; 1993 May 19; 85(10):812-7. PubMed ID: 8487326
    [Abstract] [Full Text] [Related]

  • 14. Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.
    Glick JH, Creech RH, Torri S, Holroyde C, Brodovsky H, Catalano RB, Varano M.
    Cancer; 1980 Feb 15; 45(4):735-41. PubMed ID: 6986969
    [Abstract] [Full Text] [Related]

  • 15. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
    Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, Sledge GW, Abeloff MD.
    J Clin Oncol; 1998 May 15; 16(5):1669-76. PubMed ID: 9586877
    [Abstract] [Full Text] [Related]

  • 16. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
    Neoplasma; 1985 May 15; 32(3):381-7. PubMed ID: 2862594
    [Abstract] [Full Text] [Related]

  • 17. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    Ejlertsen B, Jensen MB, Elversang J, Rasmussen BB, Andersson M, Andersen J, Nielsen DL, Cold S, Mouridsen HT.
    Eur J Cancer; 2013 Sep 15; 49(14):2986-94. PubMed ID: 23756360
    [Abstract] [Full Text] [Related]

  • 18. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women.
    Taylor SG, Gelman RS, Falkson G, Cummings FJ.
    Ann Intern Med; 1986 Apr 15; 104(4):455-61. PubMed ID: 3513684
    [Abstract] [Full Text] [Related]

  • 19. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG.
    J Clin Oncol; 1990 Sep 15; 8(9):1483-96. PubMed ID: 2202791
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PL, Bramwell VH, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA.
    J Clin Oncol; 1997 Jun 15; 15(6):2302-11. PubMed ID: 9196144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.